awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q55428234-3DFFDCD9-64EF-4053-B6C9-63CCBC3DA30A
Q55428234-3DFFDCD9-64EF-4053-B6C9-63CCBC3DA30A
BestRank
Statement
http://www.wikidata.org/entity/statement/Q55428234-3DFFDCD9-64EF-4053-B6C9-63CCBC3DA30A
Neoadjuvant chemotherapy in breast cancer: a dose-dense schedule in real life and putative role of PIK3CA mutations.
P2860
Q55428234-3DFFDCD9-64EF-4053-B6C9-63CCBC3DA30A
BestRank
Statement
http://www.wikidata.org/entity/statement/Q55428234-3DFFDCD9-64EF-4053-B6C9-63CCBC3DA30A
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
2e997acf83f5a8ece558826999aaeee0f869f0d4
P2860
A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients.